Drug Type Bispecific antibody |
Synonyms- |
Target |
Action agonists, inhibitors |
Mechanism 4-1BB agonists(Tumor necrosis factor receptor superfamily member 9 agonists), LY6G6D inhibitors(lymphocyte antigen 6 family member G6D inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neoplasms | Preclinical | China | 29 Apr 2025 |